Effects of dapagliflozin on glucolipid metabolism and levels of renal injury markers in patients with type 2 diabetes mellitus

  Objective  To analyze the influence of dapagliflozin on glucolipid metabolism status and levels of renal injury markers such as urine β₂ microglobulin (β₂-MG) and N-acetyl-β-D-glucosaminidase (NAG) in patients with type 2 diabetes mellitus (T2DM).

  Methods  The data of 54 patients with T2DM who were treated with dapagliflozin (observation group) and not treated with dapagliflozin (control group) in our hospital was retrospectively analyzed. The glucolipid metabolism, blood pressure, body weight, renal function and renal injury indicators before and after treatment and adverse reactions during treatment were recorded in the two groups.

  Results  After 24 weeks of treatment, the levels of peripheral blood fasting blood glucose (FBG), glycated hemoglobin (HbALc), body weight and body mass index (BMI) in the two groups were decreased compared with those before treatment, and the above indexes of observation group were significantly lower than those of control group (P < 0.05). The lipid metabolism indexes in the two groups were improved compared with those before treatment, but there was no statistically significant differences between two groups (P>0.05). After 24 weeks of treatment, the systolic blood pressure (SBP) and levels of urine α₁-microglobulin (α₁-MG), urine β₂-MG and urine NAG in the observation group were significantly decreased compared with those before treatment, and were significantly lower than those in the control group (P < 0.05). There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups during treatment (P>0.05).

  Conclusion  Dapagliflozin has better effects in lowering blood glucose and blood pressure in patients with T2DM, and fewer adverse reactions. It can reduce the partial renal injury markers and may have a renal protective effect.